Global Aphakia Market

1 INTRODUCTION OF GLOBAL APHAKIA MARKET
1.1 Overview of the Market
1.2 Scope of Report
1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET INTELLIGENCE
3.1 Data Mining
3.2 Validation
3.3 Primary Interviews
3.4 List of Data Sources

4 GLOBAL APHAKIA MARKET OUTLOOK
4.1 Overview
4.2 Market Dynamics
4.2.1 Drivers
4.2.2 Restraints
4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis
4.5 Regulatory Framework

5 GLOBAL APHAKIA MARKET, BY TREATMENT
5.1 Overview
5.2 Spectacles
5.2.1 +10D
5.2.2 +3-4D
5.2.3 Other
5.3 Contact Lenses
5.4 Intraocular Lens Implantation
5.5 Refractive Surgery
5.5.1 Keratophakia
5.5.2 Epikeratophakia
5.5.3 Hyperopic LASIK
5.6 Others

6 GLOBAL APHAKIA MARKET, BY CAUSE
6.1 Overview
6.2 Congenital Aphakia,
6.3 Surgical Aphakia,
6.4 Acquired Aphakia
6.4.1 Traumatic Extrusion
6.4.2 Posterior Dislocation
6.4.3 Couching
6.4.4 Other
6.5 Others

7 GLOBAL APHAKIA MARKET, BY END USER
7.1 Overview
7.2 Hospitals
7.3 Ophthalmic Clinics
7.4 Others

8 GLOBAL APHAKIA MARKET, BY GEOGRAPHY
8.1 Overview
8.2 North America Regional Market Estimates and Forecasts, 2012 - 2025
8.2.1 U.S.
8.2.2 Canada
8.2.3 Mexico
8.3 Europe Regional Market Estimates and Forecasts, 2012 - 2025
8.3.1 Germany
8.3.2 U.K.
8.3.3 France
8.3.4 Rest of Europe
8.4 Asia Pacific Regional Market Estimates and Forecasts, 2012 - 2025
8.4.1 China
8.4.2 Japan
8.4.3 India
8.4.4 Rest of Asia Pacific
8.5 Latin America Regional Market Estimates and Forecasts, 2012 - 2025
8.5.1 Brazil
8.5.2 Argentina
8.6 Rest of the World Regional Market Estimates and Forecasts, 2012 â€" 2025

9 GLOBAL APHAKIA MARKETCOMPETITIVE LANDSCAPE
9.1 Overview
9.2 Company Market Share
9.3 Vendor Landscape
9.4 Key Development Strategies

10 COMPANY PROFILES
10.1 Johnson & Johnson Services, Inc.
10.1.1 Overview
10.1.2 Financial Performance
10.1.3 Product Outlook
10.1.4 Key Developments

10.2 Ophtec BV
10.2.1 Overview
10.2.2 Financial Performance
10.2.3 Product Outlook
10.2.4 Key Developments

10.3 Novartis
10.3.1 Overview
10.3.2 Financial Performance
10.3.3 Product Outlook
10.3.4 Key Developments

10.4 ZEISS International
10.4.1 Overview
10.4.2 Financial Performance
10.4.3 Product Outlook
10.4.4 Key Developments

10.5 Rayner
10.5.1 Overview
10.5.2 Financial Performance
10.5.3 Product Outlook
10.5.4 Key Developments

10.6 Bohus BioTech AB
10.6.1 Overview
10.6.2 Financial Performance
10.6.3 Product Outlook
10.6.4 Key Developments

10.7 Lifecore Biomedical
10.7.1 Overview
10.7.2 Financial Performance
10.7.3 Product Outlook
10.7.4 Key Developments

10.8 Aetna Inc.
10.8.1 Overview
10.8.2 Financial Performance
10.8.3 Product Outlook
10.8.4 Key Developments

10.9 The Cooper Companies Inc.
10.9.1 Overview
10.9.2 Financial Performance
10.9.3 Product Outlook
10.9.4 Key Developments

10.10 Menicon Co., Ltd.
10.10.1 Overview
10.10.2 Financial Performance
10.10.3 Product Outlook
10.10.4 Key Developments

10.11 Labtician Ophthalmics, Inc.
10.11.1 Overview
10.11.2 Financial Performance
10.11.3 Product Outlook
10.11.4 Key Developments

10.12 Artificial Eye Co.
10.12.1 Overview
10.12.2 Financial Performance
10.12.3 Product Outlook
10.12.4 Key Developments

10.13 Contact Fill
10.13.1 Overview
10.13.2 Financial Performance
10.13.3 Product Outlook
10.13.4 Key Developments

10.14 ALLERGAN
10.14.1 Overview
10.14.2 Financial Performance
10.14.3 Product Outlook
10.14.4 Key Developments

10.15 MJS Lens Technology Ltd.
10.15.1 Overview
10.15.2 Financial Performance
10.15.3 Product Outlook
10.15.4 Key Developments

11 Appendix
11.1 Related Reports